Researchers investigated the potency of trimeric human nephrocystin SH3, TriSb92, a domain-derived antibody, against a conserved region in the receptor-binding domain (RBD) of the spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.
Monthly Archives: December 2021
New findings indicate that TriSb92 is a potent inhibitor of SARS-CoV-2 infection targeting a conserved site in the RBD of the spike, which is insensitive for immune escape mutations found in the relevant variants of concern, including Omicron
New evidence implies that the Omicron variant may cause a less severe and/or faster recovery from clinical COVID-19 disease.
When the most massive stars die, they collapse to form some of the densest objects known in the universe: black holes. They are the “darkest” objects in the cosmos, as not even light can escape their incredibly strong gravity. Because of this, it’s impossible to directly image black holes, making them mysterious and quite perplexing. […]
A new study provides detailed information about the molecular level binding interaction pattern of the SARS-CoV-2 Omicron and wt variant with the hACE2 receptor
New study findings suggest that both SARS-CoV-2-infected mothers and their fetuses have increased levels of inflammatory cytokines throughout gestation, which may potentially impact fetus health in the long term.
New research revealed that vaccine-breakthrough infections might elicit cross-reactive bNAbs against all variants of concern.
A new report notes menial or nil severe adverse events from vaccination against COVID-19 in children and therefore recommends COVID-19 vaccination among children aged 5-11 years old.
A new study reveals that omicron infections in South Africa are associated with lower rates of hospital admissions and lower disease severity compared to beta and delta infections.
A new study used in silico approaches for designing a next-generation CD40-targeting vaccine, CD40.